Abstract:Our results suggest that LNM plays an important role in the prognosis, and HMGB3 was potential as a biomarker for EC patients. By detecting the mutation of the risk signature, clinicians can accurately treat patients with targeted therapy, thereby improving their survival rate. Background Endometrial cancer (EC) is one of the most common malignant tumors in female reproductive system. The incidence of lymph node metastasis (LNM) is only about 10% in clinically suspected early‐stage EC patients. Discovering prognostic models and effective biomarkers for early diagnosis is important to reduce the mortality rate. Methods A least absolute shrinkage and selection operator (LASSO) regression was conducted to identify the characteristic dimension decrease and distinguish porgnostic LNM related genes signature. Subsequently, a novel prognosis‐related nomogram was constructed to predict overall survival (OS). Survival analysis was carried out to explore the individual prognostic significance of the risk model and key gene was validated in vitro. Results In total, 89 lymph node related genes (LRGs) were identified. Based on the LASSO Cox regression, 11 genes were selected for the development of a risk evaluation model. The Kaplan–Meier curve indicated that patients in the low‐risk group had considerably better OS (p = 3.583e−08). The area under the ROC curve (AUC) of this model was 0.718 at 5 years of OS. Then, we developed an OS‐associated nomogram that included the risk score and clinicopathological features. The concordance index of the nomogram was 0.769. The survival verification performed in three subgroups from the nomogram demonstrated the validity of the model. The AUC of the nomogram was 0.787 at 5 years OS. Proliferation and metastasis of HMGB3 were explored in EC cell line. External validation with 30 patients in our hospital showed that patients with low‐risk scores had a longer OS (p‐value = 0.03). Finally, we revealed that the most frequently mutated genes in the low‐risk and high‐risk groups are PTEN and TP53, respectively. Conclusions Our results suggest that LNM plays an important role in the prognosis, and HMGB3 was potential as a biomarker for EC patients.

Construction and Validation of an IHC-based Risk Model Predicting Postoperative Disease- Free Survival and Overall Survival in Chinese Endometrial Cancer Patients

Identification of a 3-Cuproptosis-associated-lncrna-signature That Predicts the Prognosis of Endometrial Cancer Patients

Identification and Validation of a Seven Cuproptosis-Associated Lncrna Signature to Predict the Prognosis of Endometrial Cancer

Identification of an Immune-Related Risk Signature and Nomogram Predicting the Overall Survival in Patients with Endometrial Cancer.

Construction of a nine DNA repair-related gene prognostic classifier to predict prognosis in patients with endometrial carcinoma

Construction and validation of a prognostic model based on 11 lymph node metastasis‐related genes for overall survival in endometrial cancer

Construction of a microenvironment immune gene model for predicting the prognosis of endometrial cancer

Identification of Potential Crucial Genes Associated With the Pathogenesis and Prognosis of Endometrial Cancer

Immunohistochemistry as a reliable predictor of remission in patients with endometrial cancer: Establishment and validation of a machine learning model

Combining Bioinformatics and Experiments to Identify and Verify Key Genes with Prognostic Values in Endometrial Carcinoma

Photosynthetic electron transport: Emergence of a concept, 1949–59

Comprehensive Analysis and Experimental Validation of a Novel Estrogen/Progesterone-Related Prognostic Signature for Endometrial Cancer

Identification and Validation of a Novel Multiomics Signature for Prognosis and Immunotherapy Response of Endometrial Carcinoma

A ten-gene methylation signature as a novel biomarker for improving prediction of prognosis and indicating gene targets in endometrial cancer

Construction of an immune-related gene prognostic model for obese endometrial cancer patients based on bioinformatics analysis

Identification Of A Metabolism-Related Signature For The Prediction Of Survival In Endometrial Cancer Patients

Risk prediction model of uterine corpus endometrial carcinoma based on immune-related genes

Heart failure: clinical problem and management issues.

A novel chromatin regulator-related immune checkpoint related gene prognostic signature and potential candidate drugs for endometrial cancer patients

Prediction of Clinical Outcome in Endometrial Carcinoma Based on a 3-lncRNA Signature

Identification of immune-related gene signature for predicting prognosis in uterine corpus endometrial carcinoma